High-throughput screening Market by Product (Service, Software), Technology {Cell-Based Assays, 2D Cell Culture, 3D Cell Culture [Scaffold-Based Technologies (Hydrogels, Inert Matrix, and Micropatterned Surfaces) Scaffold-free Technologies (Microplate, Hanging-drop Plates, Ultra-low Binding Plates)], Perfusion Cell Culture, Lab-on-a-Chip (LOC)}, and Region Global Forecast 2020 to 2030.

The HTS market is characterized by evolving industry standards and intense competition. The HTS products are subjected to regulatory approval by the FDA and other regulatory bodies throughout the world. These regulations govern a wide variety of product related activities, from quality management, design and development to labeling, manufacturing, promotion, sales and distribution. The players in the HTS market continually invest in manufacturing infrastructure to gain and maintain certifications necessary for the level of clearance.

The market players have significant R&D expenditures in order to sustain their competitive position with a continuing flow of innovative, high-quality products and services. Their research and development efforts primarily focus on potential new applications and product improvements covering wide variety of technologies, which is crucial for their operations. Their research also seeks to improve on various technical competencies in software, systems and solutions. Their workflow aims at conducting research that is focused on specific product development for release in the short-term as well as other research that is intended to be the foundation for future products over a longer time-horizon. Along with, product development the research is designed to improve products already in production, focus on major new product releases, and develop new product segments for the future. Moreover, each player looks for key strategic opportunities to align with the available markets and positions to capture market share.

Pharma & biotech companies held the largest HTS market share in 2018. Biotechnology is one of the most innovative scientific areas nowadays, with a rapid pace of progresses made every day driving the entire industry. In this sense, advances in the field have been tightly connected to both academic and industrial research, with close connections between discoveries made by research and the development of new products. This dependency encompasses a high degree of involvement between universities and industry, beneficial for both sides and especially important for reducing the time span between the development and the introduction of new products in the market.

A great majority of the value for the biotechnological industry is derived from research and development (R&D) activity in which much of the industry is based on the creation of new applications and products to the different areas of life sciences. In terms of development, because of the strict connection between biotechnology and R&D, investment in HTS research has become an essential component of these companies’ business. This obviously carries an extremely high structure of costs, with very little revenue at early stages of development. Partnerships between small and larger companies are thus essential for the survival of the first. Because of that, this has been an industry led by a small group of big companies, which are able to support these structures of costs.

Moreover, increasing government expenditure is likely to augment growth in the biotechnology industry which will further fuel HTS market. Growing pharmaceuticals market is also estimated to aid growth of HTS industry accompanying the biotech industry.

In 2018, North America was the largest market for high-throughput screening and is anticipated to retain its position by 2025. Technological advancement, ageing population, chronic diseases and government funding are some of the reasons driving HTS market growth in this region.

The U.S. health care spending increased 3.9% to reach USD 3.5 trillion, or USD 10,739 per person in 2017. Healthcare spending growth in 2017 was comparable to average growth from 2008 to 2013, which steered the more rapid growth experienced during the 2014-15 period that was marked by insurance coverage expansion and high rates of growth in retail prescription drug spending. In the U.S. the size of the HTS market means that there is unequaled purchasing power, demand, and opportunity for innovation. In contrast, by structure, reimbursement systems, regulation, issues of access, and complexity is perhaps the most opaque. Moreover, presence of prominent players and diverse biotech labs is also fueling HTS market in this region.